NextCure, Inc. (NXTC) Stock

Healthcare · Biotechnology · Member of Other US Stocks

NextCure, Inc. (NXTC) closed at USD 6.58 on 2026-10-14, a change of -36.4 % over the past year, with a market capitalization of USD 31.49M.

NextCure, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

NextCure, Inc. key figures

Previous close

USD 6.58 (2026-10-14)

1-year change

-36.4 %

Market cap

USD 31.49M

Enterprise value

USD 16.07M

P/E ratio (trailing)

-0.74

P/E ratio (forward)

-1.17

EPS (trailing)

-9.27

EPS (forward)

-5.90

PEG ratio

n/a

Price to book

2.30

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

2.01

Employees

40

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About NextCure, Inc.

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer's disease; and NC605 an antibody that targets Siglec-15, as well as chronic bone diseases, such as osteoarthritis and non-union fractures. The company also develop SIM0505, a novel antibody-drug conjugate (ADC) targeting CDH6 (cadherin-6 or K-cadherin) for the treatment of solid tumors. The company was incorporated in 2015 and is headquartered in Baltimore, Maryland.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for NextCure, Inc. and compare it with other stocks.